Evidence map›Paper›PMID 35039662›Full record

ArticleNature reviews. Endocrinology2022

Global accessibility of therapeutics for diabetes mellitus.

Michael Fralick, Alicia J Jenkins, Kamlesh Khunti, Jean Claude Mbanya, Viswanathan Mohan, Maria Inês Schmidt

Abstract read
In one paragraph

Article in Nature reviews. Endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. [Research progress on automated insulin delivery system in the field of diabetes management].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2024
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Michael FralickSinai Health System, Department of Medicine, University of Toronto, Toronto, ON, Canada. mike.fralick@mail.utoronto.ca.
Alicia J JenkinsNHMRC Clinical Trials Centre, The University of Sydney, Sydney, New South Wales, Australia. alicia.jenkins@sydney.edu.au.
Kamlesh KhuntiLeicester Diabetes Centre, University of Leicester, Leicester, UK. kk22@le.ac.uk.
Jean Claude MbanyaFaculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon. jcmbanya@yahoo.co.uk.
Viswanathan MohanDr. Mohan's Diabetes Specialities Centre & Madras Diabetes Research Foundation, Chennai, Tamil Nadu, India. drmohans@diabetes.ind.in.ORCID http://orcid.org/0000-0001-5038-6210
Maria Inês SchmidtSchool of Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil. maria.schmidt@ufrgs.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Diabetes MellitusDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2Humans

Identifiers

PMID35039662
PMCPMC8762447

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.